Melanocortin Receptor Agonists Billing & Prior-Auth Playbook

What Is the Melanocortin Receptor Agonist Drug Class?

Melanocortin receptor agonists are a pharmacologic class that bind to one or more of the five identified melanocortin receptors (MC1R, MC2R, MC3R, MC4R, MC5R). These G-protein-coupled receptors respond endogenously to alpha-melanocyte-stimulating hormone (alpha-MSH) and related peptides derived from pro-opiomelanocortin (POMC). The clinical effects differ sharply by receptor subtype, which is why the class spans dermatology, endocrinology, and sexual medicine.

Receptor Subtype Map

Each receptor subtype drives a distinct physiologic domain:

• MC1R: Pigmentation, UV-induced tanning response, anti-inflammatory signaling in skin
• MC2R: Adrenal steroidogenesis (the ACTH receptor); not a target for sexual dysfunction drugs
• MC3R: Energy homeostasis, feeding behavior, and modulation of limbic sexual circuits
• MC4R: The dominant CNS target for sexual desire and arousal; also modulates energy intake
• MC5R: Exocrine gland function; minor clinical relevance at present

Bremelanotide shows affinity at MC1R, MC3R, MC4R, and MC5R, with its pro-sexual effects attributed primarily to MC4R agonism in the hypothalamus and limbic system. A 2014 mechanistic review in the Journal of Sexual Medicine confirmed that central MC4R activation increases dopaminergic tone in mesolimbic pathways, producing desire without direct genital vasoactivity. [1]

Endogenous Ligands and the POMC System

POMC is cleaved in the anterior pituitary and the hypothalamic arcuate nucleus into alpha-MSH, beta-MSH, gamma-MSH, and ACTH. Alpha-MSH is the primary endogenous agonist at MC1R, MC3R, MC4R, and MC5R. Agouti-related peptide (AgRP) and agouti signaling protein are the endogenous inverse agonists, and their balance with alpha-MSH sets the tonic activity at MC3R and MC4R. Disruption of this balance correlates with both obesity and reduced sexual desire, which explains the mechanistic rationale for using MC4R agonists in both conditions. [2]

Approved Agents and Investigational Compounds

Bremelanotide (Vyleesi): The Only FDA-Approved MCRA for Sexual Dysfunction

The FDA granted approval to bremelanotide on June 21, 2019, under NDA 210557, for acquired, generalized HSDD in premenopausal women not attributable to a co-existing medical or psychiatric condition, relationship problems, or medication effects. [3]

Dosing: 1.75 mg subcutaneous injection administered at least 45 minutes before anticipated sexual activity. No more than one dose per 24-hour period and no more than one dose per anticipated sexual event.

Key trial data: The RECONNECT program comprised two identical Phase 3 randomized, double-blind, placebo-controlled trials (study 301 and study 302, combined N=1,247 premenopausal women). At the primary endpoint of 24 weeks, bremelanotide-treated women showed statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain score versus placebo (P<0.001) and a significant reduction in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 distress score. [4] The drug did not separate from placebo on absolute FSFI total score, a point payers frequently cite in denial letters.

Key adverse effects: Nausea occurred in 40% of bremelanotide recipients versus 1% placebo. Flushing (20%), headache (11%), and transient blood pressure elevation (mean +6 mmHg systolic lasting approximately 12 hours) are the other common reactions. Persistent hyperpigmentation of the face, gums, and breasts has been reported with chronic dosing, driven by MC1R agonism.

PT-141: The Compounded Intranasal Predecessor

PT-141 is the peptide name for bremelanotide in its original intranasal formulation. Phase 2 trials in the early 2000s used intranasal PT-141 at doses of 10 mg and 20 mg and demonstrated significant pro-erectile effects in men with erectile dysfunction as well as desire increases in women. The intranasal route was abandoned for the approved product due to dose-variable nausea at higher intranasal doses. Today, some compounding pharmacies continue to prepare PT-141 as an intranasal or subcutaneous peptide under 503A or 503B frameworks. These preparations carry no FDA approval and receive zero coverage from commercial PBMs or Medicare/Medicaid.

Setmelanotide (Imcivree): MC4R Agonism for Rare Obesity Syndromes

Setmelanotide received FDA approval in November 2020 for chronic weight management in adult and pediatric patients (age 6 and older) with obesity due to POMC deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, or leptin receptor (LEPR) deficiency confirmed by genetic testing. [5] This agent is not indicated for HSDD and sits in a separate formulary category. Prescribers working with patients who have both a qualifying rare obesity syndrome and sexual dysfunction will need separate benefit tracks for each indication.

Pipeline Agents

Several investigational MCRAs are in development. PL-8177 (oral MC4R agonist, Palatin Technologies) entered Phase 1 in 2022 targeting inflammatory bowel disease. Palatin's PL-3994 targets natriuretic peptide receptor A. None have progressed to Phase 3 for sexual dysfunction as of this writing.

Pharmacokinetics Relevant to Prior-Auth Documentation

Understanding bremelanotide's PK profile helps when writing clinical rationale letters. Subcutaneous bioavailability is approximately 100% for the 1.75 mg dose. Peak plasma concentration (Tmax) is reached within 1 hour. Protein binding is 21%. The drug is metabolized by hydrolysis of the amide bonds; no CYP450 involvement means minimal drug-drug interaction liability, which is a meaningful differentiator from flibanserin (Addyi) for patients on CYP3A4 inhibitors. Half-life is approximately 2.7 hours. Renal excretion accounts for 64.8% of administered dose. [6]

This matters for formulary arguments: if a plan requires flibanserin trial-and-failure before bremelanotide, and the patient takes a moderate CYP3A4 inhibitor, the CYP profile of bremelanotide provides a documented contraindication-based reason to skip that step-therapy requirement.

ICD-10, CPT, and NDC Coding Reference

Accurate coding is the first line of defense against automatic prior-auth denials.

Diagnosis Codes

| ICD-10 | Description | |--------|-------------| | F52.0 | Hypoactive sexual desire disorder | | F52.22 | Female sexual arousal disorder | | N95.0 | Postmenopausal bleeding (use cautiously; Vyleesi is not approved postmenopause) | | F52.8 | Other sexual dysfunction not due to a substance or known physiological condition |

The FDA label restricts bremelanotide to premenopausal women. F52.0 is the tightest code match for HSDD and should appear as the primary diagnosis on every claim.

NDC and J-Code

• NDC (Vyleesi 1.75 mg/0.3 mL single-dose auto-injector): 70771-1001-01
• J-code: No permanent J-code has been assigned. Bill with J3490 (unclassified drugs) or J3590 (unclassified biologic) and attach a narrative description of the drug, dose, and NDC.
• HCPCS: Some payers accept S-codes for sexual dysfunction medications; verify with each plan before submission.

CPT for the Encounter

• 99213 or 99214 (office or outpatient E/M, established patient) for the prescribing visit
• 96372 (therapeutic injection, subcutaneous or intramuscular) if administered in-office for training
• G0101 is not applicable here; do not use OB/GYN preventive codes for this visit

Prior Authorization: Step-by-Step Playbook

Prior authorization for Vyleesi is required by virtually every commercial plan, most state Medicaid programs, and every Part D plan that covers the drug at all. The following workflow reflects current PBM practices at Express Scripts, CVS Caremark, and OptumRx as of 2024.

Step 1: Confirm Formulary Status Before Prescribing

Call the plan or use the payer's real-time formulary tool. Vyleesi sits on Tier 4 or Tier 5 (specialty) on most formularies, with PA required regardless of tier. Some plans exclude it entirely under "lifestyle drug" carve-outs. If excluded, document the exclusion and pivot to an appeals or exception pathway immediately. Do not send a PA to a plan that has a blanket exclusion; file a medical necessity exception instead.

Step 2: Gather Required Documentation Before Submission

Every major PBM requires at minimum:

1. Confirmed diagnosis of HSDD (F52.0) documented in the chart with onset, duration, and severity
2. Confirmation that the patient is premenopausal (last menstrual period date or FSH level <40 mIU/mL)
3. Documentation that HSDD is acquired and generalized (not situational or lifelong)
4. Exclusion of reversible causes: depression, relationship distress, medications (SSRIs, antipsychotics, hormonal contraceptives)
5. For OptumRx and CVS Caremark: evidence of prior trial of flibanserin (Addyi) unless contraindicated

The flibanserin step-therapy requirement is the most common barrier. Flibanserin is contraindicated with alcohol use and with moderate-to-strong CYP3A4 inhibitors (fluconazole, itraconazole, diltiazem, erythromycin, grapefruit). Document any of these as a contraindication to satisfy the step-therapy waiver on clinical grounds.

Step 3: Write the Clinical Rationale Letter

Do not submit the auto-generated form alone. Attach a signed letter from the prescriber. Effective letters contain:

• Patient age and menopausal status with corroborating lab value
• DSM-5 criteria for HSDD met (specify duration of at least 6 months, personal distress using a validated scale such as the FSDS-DAO)
• Treatments trialed and failed or contraindicated: counseling, hormonal optimization, medication adjustments
• Why bremelanotide is medically necessary versus alternatives
• Reference to RECONNECT trial data showing statistically significant improvement on FSDS-DAO Item 13 [4]

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 213 states: "Sexual dysfunction, including HSDD, is a medical condition that warrants the same attention and treatment access as other chronic conditions affecting quality of life." [7] Quoting this in the letter directly counteracts "lifestyle drug" denial language.

Step 4: Turnaround and Escalation Timeline

| Day | Action | |-----|--------| | Day 0 | Submit PA with full documentation | | Day 3 | Follow up by phone if no acknowledgment | | Day 7 | Standard non-urgent PA decision expected (most states require 14-day max) | | Day 8 | If denied, request peer-to-peer review within 24 hours of denial notice | | Day 10 | Peer-to-peer call with PBM medical director | | Day 14 | File first-level appeal if peer-to-peer fails | | Day 30 | File external independent review if first-level appeal denied |

Most successful overturns happen at the peer-to-peer stage. The prescribing clinician (MD, DO, NP, or PA) must personally conduct this call; delegating to office staff is not permitted under most payer contracts.

Step 5: External Appeal and State Mandates

Nineteen states have enacted laws requiring coverage parity for sexual dysfunction drugs when the plan covers erectile dysfunction medications (PDE5 inhibitors). If the patient's plan covers sildenafil or tadalafil and denies Vyleesi on a "lifestyle exclusion," cite the applicable state parity statute in the external appeal letter. This argument has been effective in California, Illinois, and New York based on case precedent reported by the Endocrine Society advocacy office.

Flibanserin vs. Bremelanotide: Positioning in the PA Context

Payers increasingly require flibanserin (Addyi) trial-and-failure before approving bremelanotide. Clinicians need a working comparison to justify skipping flibanserin:

| Feature | Flibanserin (Addyi) | Bremelanotide (Vyleesi) | |---------|---------------------|--------------------------| | Mechanism | 5-HT1A agonist / 5-HT2A antagonist / D4 partial agonist | MC3R/MC4R agonist | | Dosing | 100 mg oral, every night at bedtime | 1.75 mg SC, as needed | | Alcohol interaction | Contraindicated; FDA REMS required | No restriction | | CYP3A4 inhibitor interaction | Contraindicated | No clinically significant interaction | | Onset of effect | 4 to 8 weeks of daily dosing | 45 minutes | | Common adverse effects | Somnolence, dizziness, hypotension | Nausea, flushing, BP elevation | | FDA approval year | 2015 | 2019 |

When a patient cannot adhere to nightly dosing, has significant alcohol use, or takes a CYP3A4 inhibitor, flibanserin is contraindicated and step-therapy should be waived. Document each criterion explicitly. The Endocrine Society's 2019 Female Sexual Dysfunction clinical practice guideline notes that on-demand pharmacotherapy may be preferable for patients whose sexual activity is infrequent or unpredictable. [8]

Compounded PT-141: Billing Reality

Compounded PT-141 (bremelanotide) is not covered by any commercial insurance, Medicare Part D, or Medicaid. Period. Patients pay cash. The typical compounding pharmacy price for PT-141 2 mg/mL subcutaneous solution (10 mL vial) ranges from $90 to $250 depending on the pharmacy and whether it is a 503A or 503B compounder.

For telehealth platforms prescribing compounded PT-141, the billing structure is straightforward: charge a consultation fee under 99213 or 99202 for a new telehealth patient (or 99203 for higher-complexity new patients), bill the appropriate telehealth modifier (95 for audio-video, 93 for audio-only), and document that the patient received counseling on the unapproved status of the compounded product.

The FDA's 2023 guidance on compounding and the 503B outsourcing facility framework specifically noted that peptides like PT-141 are not on the FDA-approved drug shortage list and therefore cannot be lawfully compounded by 503B facilities for office stock. [9] Document that any compounded PT-141 is prescribed for an individually identified patient under 503A rules.

Special Populations and Prescribing Considerations

Postmenopausal Women

Vyleesi is not FDA-approved for postmenopausal women. The RECONNECT trials excluded them. Prescribing to postmenopausal patients is off-label. For postmenopausal HSDD, the Endocrine Society and the North American Menopause Society (NAMS) both recommend optimizing systemic or local estrogen and testosterone before introducing pharmacologic desire agents. NAMS 2022 position statement on hormone therapy states that low-dose vaginal estrogen effectively treats genitourinary syndrome of menopause (GSM), which may coexist with or masquerade as HSDD. [10]

Men with Sexual Dysfunction

No melanocortin receptor agonist is FDA-approved for men. Phase 2 data with intranasal PT-141 (10 mg, 20 mg) showed significant pro-erectile effects in men with psychogenic erectile dysfunction who did not respond to visual sexual stimulation alone, with a response rate of 67% versus 17% placebo. [11] Men seeking compounded PT-141 represent an off-label, cash-pay population. Document informed consent including the off-label status and the absence of long-term safety data.

Cardiovascular Considerations

The transient systolic blood pressure increase of approximately 6 mmHg following bremelanotide injection is clinically relevant in patients with known hypertension or baseline systolic BP above 140 mmHg. The Vyleesi prescribing information recommends against use in patients with known cardiovascular disease or uncontrolled hypertension. Check BP at baseline and remind patients not to use the drug within 8 hours of taking a phosphodiesterase-5 inhibitor, as additive hypotension could occur on the declining side of the BP curve. [6]

Documentation Checklist for Medical Records

Thorough records serve two purposes: they support PA submissions and they protect the practice during payer audits.

Minimum chart elements for every HSDD/bremelanotide visit:

• Chief complaint and duration of symptoms (at least 6 months per DSM-5)
• Validated distress scale score (FSDS-DAO, FSFI, or BISF-W)
• Menopausal status with corroborating evidence (LMP date or FSH)
• Exclusion of depression (PHQ-9 score), relationship distress (brief screen), and causative medications
• Relevant labs: TSH, prolactin, total and free testosterone, FSH if indicated
• Informed consent for bremelanotide covering nausea risk, BP elevation, hyperpigmentation, and off-label status if applicable
• Patient education on injection technique, timing (45 minutes before activity), and maximum frequency (one dose per 24 hours)

Reimbursement Benchmarks

A 4-pack carton of Vyleesi (four auto-injectors) carries an AWP near $1,190. After PBM negotiation, net cost to the plan typically falls to $700 to $900. Patient cost-sharing depends on tier placement.

Palatin Technologies (the manufacturer) offers a copay assistance card reducing patient out-of-pocket to $0 for eligible commercially insured patients, with a maximum benefit of $3,000 per year. This card cannot be used for government insurance (Medicare, Medicaid, TRICARE). Patients on government insurance who meet income criteria may qualify for the manufacturer's patient assistance program (PAP).

For cash-pay patients or those with excluded coverage, the GoodRx price for a single Vyleesi auto-injector ranges from $220 to $290 depending on the pharmacy.